Where can I get the Japanese version of Pharma R&D Annual Review 2026?

You can download the full report from the Citeline website.

What is the main reason for the decrease in the R&D pipeline?

It is largely due to the impact of data cleaning and normalization, primarily in the preclinical stage.

Which country has the largest share of R&D company headquarters?

The US holds the largest share at 41%, followed by China at 19%.

Which therapeutic area has the highest number of clinical trials?

Oncology, with 20,383 trials confirmed.

AI News NQ Analysis

Citeline Releases Japanese Version of 'Pharma R&D Annual Review 2026' Analyzing Global Pharmaceutical R&D Trends

NQ Score 0/100

N1 Content Completeness 8

Key facts

Citeline Releases Japanese Version of 'Pharma R&D Annual Review 2026' Analyzing Global Pharmaceutical R&D Trends
Citeline has released the Japanese version of its 'Pharma R&D Annual Review 2026'. The global pharmaceutical R&D pipeline totals 22,940 products, a 3.92% decrease from the previous year, but the long-term expansion trend remains. The US holds the largest share at 41%, while China has expanded its presence to 19%.
Source: PR TIMES
Date: Thu Jun 11 2026 11:00:02 GMT+0900 (Japan Standard Time)

Direct answer

Citeline has released the Japanese version of its 'Pharma R&D Annual Review 2026'. The global pharmaceutical R&D pipeline totals 22,940 products, a 3.92% decrease from the previous year, but the long-term expansion trend remains. The US holds the largest share at 41%, while China has expanded its presence to 19%.

Citation: Citeline Releases Japanese Version of 'Pharma R&D Annual Review 2026' Analyzing Global Pharmaceutical R&D Trends (Thu Jun 11 2026 11:00:02 GMT+0900 (Japan Standard Time)), PR TIMES
Source: PR TIMES
Date: Thu Jun 11 2026 11:00:02 GMT+0900 (Japan Standard Time)

AI Summary (NQ-processed)

Citeline has released the Japanese version of its 'Pharma R&D Annual Review 2026'. The global pharmaceutical R&D pipeline totals 22,940 products, a 3.92% decrease from the previous year, but the long-term expansion trend remains. The US holds the largest share at 41%, while China has expanded its presence to 19%.

AI Analysis

Frequently Asked Questions

Q: Where can I get the Japanese version of Pharma R&D Annual Review 2026?: A: You can download the full report from the Citeline website.
Q: What is the total number of global pharmaceutical R&D pipelines in 2026?: A: 22,940 products, a 3.92% decrease from the previous year.
Q: What is the main reason for the decrease in the R&D pipeline?: A: It is largely due to the impact of data cleaning and normalization, primarily in the preclinical stage.
Q: Which country has the largest share of R&D company headquarters?: A: The US holds the largest share at 41%, followed by China at 19%.
Q: Which therapeutic area has the highest number of clinical trials?: A: Oncology, with 20,383 trials confirmed.